Facebook Twitter LinkedIn Instagram Email Printer Google Plus

Martin Graf

Partner, Health and Life Sciences, Oliver Wyman

A conversation around what the future holds for AI, the insurer mix shift, and more. 

Founder and CEO, Softheon
Partner, Health and Life Sciences, Oliver Wyman

With bid season approaching, payers' pharmacy teams must re-evaluate how to competitively position themselves for success.

Partner, Health and Life Sciences, Oliver Wyman
Engagement Manager, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman
Associate, Health and Life Sciences, Oliver Wyman
Senior Consultant, Oliver Wyman

How extended periods of suppressed utilization and a regulatory pause on record collection may influence plans' anticipated results next year.

Principal, Health and Life Sciences, Organizational Effectiveness, Oliver Wyman
Senior Advisor, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Considerations for the pricing of health insurance products amidst a global crisis.

Partner, Health and Life Sciences, Oliver Wyman
Senior Advisor, Health & Life Sciences, Oliver Wyman

Four tactical considerations to ensure your pandemic reaction is expedited, purposeful, and meaningful.

Principal, Health and Life Sciences, Organizational Effectiveness, Oliver Wyman
Senior Advisor, Health and Life Sciences, Oliver Wyman
Principal, Health and Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe

By 2030, 20% of the US will be over 65. Boomers represent the biggest, most lucrative MA growth segment.

Co-Founder and CEO, Clover Health
CEO, Alignment Healthcare
Former President of Government Business, Anthem/BCBSM, Senior Adviser, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Why a focus on the provider is needed to achieve 4 or 5 Stars.

Partner, Health and Life Sciences, Oliver Wyman

New analysis details how far ‘all in’ provider organizations have to go to reap risk rewards.

Partner, Health and Life Sciences, Oliver Wyman

Details on the final Call Letter and advice for where plans should place their strategic focus in 2018.

Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

CMS Star Ratings are do-or-die for health plans. And this year, the bar is higher than ever. Our latest analysis finds that a health plan’s Star rating is defined primarily by the behavior of its providers.

Associate, Oliver Wyman
Partner, Health & Life Sciences, Oliver Wyman
Partner, Health and Life Sciences, Oliver Wyman

Insights in your inbox

Subscribe